Article: Nicotinamide Riboside Reduces and Prevents Chemotherapy-Induced Peripheral Neuropathy: Preclinical Findings

PrevNext
Neurological Health Neuropathy Preclinical

Nicotinamide Riboside Reduces and Prevents Chemotherapy-Induced Peripheral Neuropathy: Preclinical Findings

Synopsis

Chemotherapy often causes peripheral neuropathy with no effective treatments. This study showed that NR, which activates the NAD-dependent enzyme SIRT2, prevents and reverses nerve damage caused by cisplatin chemotherapy in mice. NR's protective effects require SIRT2 but do not reduce chemotherapy's ability to kill cancer cells—in some cases, NR may enhance cancer cell sensitivity. These findings highlight NR as a potential therapy to reduce chemotherapy nerve toxicity.

Journal

Neuro-Oncology Advances

Share

Read more

Inflammation

Nicotinamide Riboside Helps Prevent Obesity, Inflammation, and Fibrosis: Preclinical Findings

SynopsisNR supplementation was tested in young and old obese female mice to see if it reduces liver inflammation and fibrosis. In old mice, NR decreased weight gain, fat mass, and improved glucose ...

Read more
Metabolic Health

Nicotinamide Riboside and Dihydronicotinic Acid Riboside Synergistically Increase NAD+ Levels: Preclinical Findings

SynopsisEukaryotic cells use multiple molecules as NAD+ precursors, but how they work together is unclear. This study identified dihydronicotinic acid riboside (NARH) as a new NAD+ precursor in liv...

Read more